Doing the Right Thing for the Wrong Reason

In this issue of the International Journal of Radiation Oncology • Biology • Physics (the Red Journal), Tao et al (1) report the results of a phase 3, randomized, placebo-controlled trial of a glycosaminoglycan analog (OTD70DERM) for reduction of radiation-associated skin toxicity in patients treated with radiation and concurrent cetuximab. The authors should be commended for the rigor of the study, which included a double-blinded design, independent review of photographs by an expert panel, and longitudinal patient-reported quality of life measures.

http://ift.tt/2w614ah